You have 9 free searches left this month | to do more

Atezolizumab

Atezolizumab is a drug used to treat Breast Cancer, Non-Small Cell Lung Cancer, Urothelial Carcinoma, and other conditions. Atezolizumab is being actively studied in 327 studies and prior, has been studied in 42.

Top SponsorsTop SitesTop Investigators
Hoffmann-La RocheAsan Medical CenterAslaug Helland
National Cancer Institute (NCI)Seoul National University HospitalDwight Owen
Genentech, Inc.Samsung Medical CenterGulam Manji
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
Recruiting
  • Ovarian Endometrioid Tumor
  • +3 more
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
2021-10-21
Oct 21, 2021
M
Completed
  • Urothelial/Bladder Cancer, Nos
  • Atezolizumab
  • +3 more
  • New York, New York
    Icahn School of Medicine at Mount Sinai
2022-03-07
Mar 7, 2022
W
Active, not recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
2022-02-16
Feb 16, 2022
T
Not yet recruiting
  • Colorectal Cancer Metastatic
  • Scottsdale, Arizona
  • +2 more
2022-02-07
Feb 7, 2022
F
Recruiting
  • Invasive Bladder Cancer
  • Madrid, Spain
    Hospital 12 de Octubre
2022-02-08
Feb 8, 2022
F
Recruiting
  • HER2-positive Breast Cancer
  • Atezolizumab
  • +3 more
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
2022-01-19
Jan 19, 2022
G
Recruiting
  • Metastatic or Locally Advanced Malignancies
  • Berlin, Germany
  • +5 more
2022-03-21
Mar 21, 2022
N
Recruiting
  • Advanced Hepatocellular Carcinoma
  • Singapore, Singapore
    National University Hospital
2021-10-27
Oct 27, 2021
H
Recruiting
  • Cervical Cancer
  • +2 more
  • Stereotactic body radiation therapy (SBRT)
  • Atezolizumab
  • Tampa, Florida
  • +1 more
2022-01-26
Jan 26, 2022
W
Withdrawn
  • Non-small Cell Lung Cancer
  • +3 more
  • (no location specified)
2021-10-28
Oct 28, 2021
T
Not yet recruiting
  • Hepatocellular Carcinoma
  • Hepatocellular Cancer
  • Houston, Texas
    Houston Methodist Research Institute
2022-01-05
Jan 5, 2022
I
Recruiting
  • Small Cell Lung Cancer Extensive Stage
  • Thoracic Radiotherapy
  • Atezolizumab
  • thoracic radiotherapy (TRT)
  • Linz, Austria
  • +1 more
2021-08-25
Aug 25, 2021
D
Recruiting
  • Breast Cancer
  • +3 more
  • Atezolizumab
  • Sacituzumab govitecan
  • Boston, Massachusetts
  • +2 more
2022-03-15
Mar 15, 2022
U
Active, not recruiting
  • Endometrial Cancer
  • Birmingham, Alabama
  • +2 more
2022-02-21
Feb 21, 2022
M
Recruiting
  • Breast Cancer
  • Triple Negative Breast Cancer
  • Birmingham, Alabama
  • +1 more
2022-03-22
Mar 22, 2022
D
Suspended
  • Non Small Cell Lung Cancer
  • Durham, North Carolina
    Duke University Medical Center
2021-12-08
Dec 8, 2021
B
Active, not recruiting
  • Tumor, Solid
  • Los Angeles, California
  • +4 more
2022-02-28
Feb 28, 2022
T
Recruiting
  • Rectal Cancer
  • Amsterdam, Noord-Holland, Netherlands
    Marieke van de Belt
2021-04-19
Apr 19, 2021
H
Not yet recruiting
  • Non Small Cell Lung Cancer
  • Atezolizumab
  • Changsha, Hunan, China
    Hunan Cancer hospital
2022-03-16
Mar 16, 2022
O
Active, not recruiting
  • Cancer, Breast
  • Triple Negative Breast Cancer
  • Atezolizumab
  • +3 more
  • Copenhagen, Denmark
  • +4 more
2022-03-04
Mar 4, 2022
T
Active, not recruiting
  • Solid Tumor
  • Metastatic Cancer
  • Birmingham, Alabama
  • +3 more
2022-03-31
Mar 31, 2022
U
Recruiting
  • Castration-Resistant Prostate Carcinoma
  • +4 more
  • Atezolizumab
  • Cabozantinib S-malate
  • Salt Lake City, Utah
    Huntsman Cancer Institute/University of Utah
2022-03-11
Mar 11, 2022
U
Recruiting
  • Bile Duct Cancer
  • +8 more
  • Gainesville, Florida
    University of Florida
2021-11-15
Nov 15, 2021